viewXPhyto Therapeutics Corp.

XPhyto Therapeutics' Germany subsidiary inks R&D agreement with a Munich university and brewery

The company will explore the science of CBD-infused drinks at the International Beverage Research Center

"We are particularly looking forward to the development of cannabis infused fermented beverages and sports drinks," VP of European Corporate Development Robert Barth said.

XPhyto Therapeutics Corp (CSE:XPHY) announced Monday that its German subsidiary Bunker Pflanzenextrakte GmbH signed an exclusive cannabis research and development agreement with the Technical University of Munich.

The deal was made with the chair of brewing and beverage technology, part of the School of Life Sciences at Weihenstephan, the company said in a statement.

Weihenstephan is the site of International Beverage Research Center, a Bavarian brewery and state-of-the-art research facility. The plant contains the entire chain of beverage production, and researchers can study molecular biology, biotechnology and more.

READ: XPhyto Therapeutics acquires German narcotics company Vektor

For XPhyto, that means diving into the science of cannabidiol (CBD)-infused drinks. The research agreement will target various approaches for the use of cannabis plants as well as testing the chemical-physical compatibility of cannabis materials with various food and beverages.

"Given the commercial potential for CBD-infused beverages in Europe, XPhyto is very pleased to have secured such a strong development partner right here in Bavaria," XPhyto VP of European Corporate Development and Bunker Managing Director Robert Barth said in a statement. "We are excited to work together and we are particularly looking forward to the development of cannabis infused fermented beverages and sports drinks."

The company's stock ticked 2.2% lower Monday to $1.31.

—Updated to include share movement—

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com 

Follow him on Twitter @andrew_kessel

Quick facts: XPhyto Therapeutics Corp.


Price: 1.4 CAD

Market Cap: $97.67 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


XPhyto Therapeutics takes a major step forward launching first commercial...

XPhyto Therapeutics CEO Hugh Rogers joined Steve Darling from Proactive to share details the company and their partner 3a-diagnostics have successfully registered their first biosensor test in oral inflammation with the German authorities. Rogers telling Proactive this will be an at-home...

3 weeks, 6 days ago

2 min read